Synopsis
Synopsis
0
VMF
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. 3,3',5-triiodothyronine
2. Cytomel
3. Liothyronine
4. T3 Thyroid Hormone
5. Thyroid Hormone, T3
6. Triiodothyronine
1. 55-06-1
2. Cytomel
3. Triostat
4. 3,3',5-triiodo-l-thyronine Sodium Salt
5. Tertroxin
6. T3 Sodium Salt
7. Basoprocin
8. Ibiothyron
9. Cynomel
10. Triiodothyronine Sodium
11. L-triiodothyronine Sodium Salt
12. Cytobin
13. 3,3',5-triiodo-l-thyronine Sodium
14. 3,3',5-triiodothyronine Sodium Salt
15. Triiodothyronine Sodium Salt
16. L-tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-, Monosodium Salt
17. Liotrix (t3)
18. Chebi:6484
19. Liothyronine (sodium)
20. Monosodium L-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine
21. Gca9vv7d2n
22. Liothyronine (l- Isomer) Sodium
23. Rathyronine Sodium, (s)-
24. Cytomel Sodium
25. Lyothyronin
26. Nsc-80774
27. Nsc-758175
28. 3,3'',5-triiodo-l-thyronine Sodium Salt
29. Ro Thyronine
30. Sodium Triiodothyronine
31. Liothyronine Sodium Salt
32. Alanine, 3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)-, Monosodium Salt, L-
33. Sodium Liothyronine
34. Sodium T3
35. Sodium Triiodotironine
36. Sodium-l-triiodothyronine
37. Mls000028648
38. L-triiodothyronine Hydrochloride
39. Sodium (s)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoate
40. Rathyronine Hydrochloride, (s)-
41. Sodium Triiodothyronine, L-
42. Sodium 3,5,3'-triiodothyronine
43. Sodium L-3,5,3'-triiodothyronine
44. Smr000059206
45. Einecs 200-223-5
46. Unii-gca9vv7d2n
47. Mfcd00002594
48. Nsc 80774
49. Sodium 3,3',5-triiodo-l-thyronine
50. Sodium 3,5,3'-triiodo-l-thyronine
51. L-3,3',5-triiodothyronine Sodium Salt
52. Triostat (tn)
53. Cytomel (tn)
54. Liothyronine Sodium [usp:ban:jan]
55. Ibiot
56. L-tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-, Sodium Salt (1:1)
57. Sodium;(2s)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate
58. O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-l-tyrosine Sodium Salt
59. T-3
60. Epitope Id:136777
61. T3 (liotrix)
62. T3, Na
63. Dsstox_cid_27505
64. Dsstox_rid_82385
65. Dsstox_gsid_47505
66. Schembl41654
67. 3,3',5-l-triiodothyronine
68. Spectrum1502047
69. Chembl1201119
70. Dtxsid8047505
71. Liothyronine Sodium [jan]
72. Nrp-409
73. Liothyronine Sodium (jp17/usp)
74. Hms1921h18
75. Hms2092b14
76. Liothyronine Sodium [vandf]
77. Act03263
78. Amy38143
79. Hy-a0070
80. Liothyronine Sodium [mart.]
81. Sodium L-3,3',5-triiodothyronine
82. Tox21_302514
83. Triiodothyronine Sodium, Levo
84. Ccg-39522
85. Liothyronine Sodium [usp-rs]
86. Liothyronine Sodium [who-dd]
87. Liotrix (t3) [orange Book]
88. S4217
89. Liothyronine Sodium Salt [mi]
90. Akos015918421
91. Akos032949712
92. Cs-3241
93. 3,3',5-triiodo-l-thyronine (sodium)
94. Cas-55-06-1
95. Liothyronine Sodium [green Book]
96. Liothyronine Sodium [orange Book]
97. Ncgc00256816-01
98. Ac-31934
99. As-13674
100. L-3,3',5-triiodothyronine, Sodium Salt
101. Liothyronine Sodium [ep Monograph]
102. Liothyronine Sodium [usp Monograph]
103. 3,5,3'-triiodo-l-thyronine Monosodium Salt
104. Sw219577-1
105. D01011
106. F20556
107. A830467
108. Q930170
109. Q-201881
110. 3,3',5-triiodo-l-thyronine Sodium Salt, >=95% (hplc)
111. Liothyronine Sodium, European Pharmacopoeia (ep) Reference Standard
112. O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-l-tyrosine, Monosodium Salt
113. 3,3',5-triiodo-l-thyronine Sodium Salt, Powder, Bioreagent, Suitable For Cell Culture
114. Liothyronine For Peak Identification, European Pharmacopoeia (ep) Reference Standard
115. Sodium (2s)-2-amino-3-[4-(4-hydroxy-3-iodo-phenoxy)-3,5-diiodo-phenyl]propanoate
116. Sodium (2s)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate
117. 3,3',5-triiodo-l-thyronine Sodium Salt, Gamma-irradiated, Powder, Bioxtra, Suitable For Cell Culture
Molecular Weight | 672.95 g/mol |
---|---|
Molecular Formula | C15H11I3NNaO4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 5 |
Exact Mass | 672.7720 g/mol |
Monoisotopic Mass | 672.7720 g/mol |
Topological Polar Surface Area | 95.6 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 408 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 6 | |
---|---|
Drug Name | Cytomel |
PubMed Health | Liothyronine |
Drug Classes | Diagnostic Agent, Thyroid Function, Thyroid Supplement |
Drug Label | Thyroid hormone drugs are natural or synthetic preparations containing tetraiodothyronine (T4, levothyroxine) sodium or triiodothyronine (T3, liothyronine) sodium or both. T4 and T3 are produced in the human thyroid gland by the iodination and coupli... |
Active Ingredient | Liothyronine sodium |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 0.05mg base; eq 0.025mg base; eq 0.005mg base |
Market Status | Prescription |
Company | King Pharms R And D |
2 of 6 | |
---|---|
Drug Name | Liothyronine sodium |
Drug Label | Thyroid hormone drugs are natural or synthetic preparations containing tetraiodothyronine (T4, levothyroxine) sodium or triiodothyronine (T3, liothyronine) sodium or both. T4 and T3 are produced in the human thyroid gland by the iodination and coupli... |
Active Ingredient | Liothyronine sodium |
Dosage Form | Tablet; Injectable |
Route | Injection; Oral |
Strength | eq 0.05mg base; eq 0.025mg base; eq 0.005mg base; eq 0.01mg base/ml |
Market Status | Prescription |
Company | X Gen Pharms; Coastal Pharms; Sigmapharm Labs; Mylan |
3 of 6 | |
---|---|
Drug Name | Triostat |
PubMed Health | Liothyronine |
Drug Classes | Diagnostic Agent, Thyroid Function, Thyroid Supplement |
Active Ingredient | Liothyronine sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 0.01mg base/ml |
Market Status | Prescription |
Company | Par Sterile Products |
4 of 6 | |
---|---|
Drug Name | Cytomel |
PubMed Health | Liothyronine |
Drug Classes | Diagnostic Agent, Thyroid Function, Thyroid Supplement |
Drug Label | Thyroid hormone drugs are natural or synthetic preparations containing tetraiodothyronine (T4, levothyroxine) sodium or triiodothyronine (T3, liothyronine) sodium or both. T4 and T3 are produced in the human thyroid gland by the iodination and coupli... |
Active Ingredient | Liothyronine sodium |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 0.05mg base; eq 0.025mg base; eq 0.005mg base |
Market Status | Prescription |
Company | King Pharms R And D |
5 of 6 | |
---|---|
Drug Name | Liothyronine sodium |
Drug Label | Thyroid hormone drugs are natural or synthetic preparations containing tetraiodothyronine (T4, levothyroxine) sodium or triiodothyronine (T3, liothyronine) sodium or both. T4 and T3 are produced in the human thyroid gland by the iodination and coupli... |
Active Ingredient | Liothyronine sodium |
Dosage Form | Tablet; Injectable |
Route | Injection; Oral |
Strength | eq 0.05mg base; eq 0.025mg base; eq 0.005mg base; eq 0.01mg base/ml |
Market Status | Prescription |
Company | X Gen Pharms; Coastal Pharms; Sigmapharm Labs; Mylan |
6 of 6 | |
---|---|
Drug Name | Triostat |
PubMed Health | Liothyronine |
Drug Classes | Diagnostic Agent, Thyroid Function, Thyroid Supplement |
Active Ingredient | Liothyronine sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 0.01mg base/ml |
Market Status | Prescription |
Company | Par Sterile Products |
H - Systemic hormonal preparations, excl. sex hormones and insulins
H03 - Thyroid therapy
H03A - Thyroid preparations
H03AA - Thyroid hormones
H03AA02 - Liothyronine sodium
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Liothyronine Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Liothyronine Sodium, including repackagers and relabelers. The FDA regulates Liothyronine Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Liothyronine Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Liothyronine Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Liothyronine Sodium supplier is an individual or a company that provides Liothyronine Sodium active pharmaceutical ingredient (API) or Liothyronine Sodium finished formulations upon request. The Liothyronine Sodium suppliers may include Liothyronine Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Liothyronine Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Liothyronine Sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Liothyronine Sodium active pharmaceutical ingredient (API) in detail. Different forms of Liothyronine Sodium DMFs exist exist since differing nations have different regulations, such as Liothyronine Sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Liothyronine Sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Liothyronine Sodium USDMF includes data on Liothyronine Sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Liothyronine Sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Liothyronine Sodium suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Liothyronine Sodium Drug Master File in Japan (Liothyronine Sodium JDMF) empowers Liothyronine Sodium API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Liothyronine Sodium JDMF during the approval evaluation for pharmaceutical products. At the time of Liothyronine Sodium JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Liothyronine Sodium suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Liothyronine Sodium Drug Master File in Korea (Liothyronine Sodium KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Liothyronine Sodium. The MFDS reviews the Liothyronine Sodium KDMF as part of the drug registration process and uses the information provided in the Liothyronine Sodium KDMF to evaluate the safety and efficacy of the drug.
After submitting a Liothyronine Sodium KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Liothyronine Sodium API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Liothyronine Sodium suppliers with KDMF on PharmaCompass.
A Liothyronine Sodium CEP of the European Pharmacopoeia monograph is often referred to as a Liothyronine Sodium Certificate of Suitability (COS). The purpose of a Liothyronine Sodium CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Liothyronine Sodium EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Liothyronine Sodium to their clients by showing that a Liothyronine Sodium CEP has been issued for it. The manufacturer submits a Liothyronine Sodium CEP (COS) as part of the market authorization procedure, and it takes on the role of a Liothyronine Sodium CEP holder for the record. Additionally, the data presented in the Liothyronine Sodium CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Liothyronine Sodium DMF.
A Liothyronine Sodium CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Liothyronine Sodium CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Liothyronine Sodium suppliers with CEP (COS) on PharmaCompass.
A Liothyronine Sodium written confirmation (Liothyronine Sodium WC) is an official document issued by a regulatory agency to a Liothyronine Sodium manufacturer, verifying that the manufacturing facility of a Liothyronine Sodium active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Liothyronine Sodium APIs or Liothyronine Sodium finished pharmaceutical products to another nation, regulatory agencies frequently require a Liothyronine Sodium WC (written confirmation) as part of the regulatory process.
click here to find a list of Liothyronine Sodium suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Liothyronine Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Liothyronine Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Liothyronine Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Liothyronine Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Liothyronine Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Liothyronine Sodium suppliers with NDC on PharmaCompass.
Liothyronine Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Liothyronine Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Liothyronine Sodium GMP manufacturer or Liothyronine Sodium GMP API supplier for your needs.
A Liothyronine Sodium CoA (Certificate of Analysis) is a formal document that attests to Liothyronine Sodium's compliance with Liothyronine Sodium specifications and serves as a tool for batch-level quality control.
Liothyronine Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Liothyronine Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Liothyronine Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Liothyronine Sodium EP), Liothyronine Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Liothyronine Sodium USP).
LOOKING FOR A SUPPLIER?